Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00767572 · ClinicalTrials.gov registry record · Phase 4

Statins and Endothelial Function in Patients With Coarctation of the Aorta

A Phase 4 study, sponsored by University of California, San Francisco.

Terminated
Registry status
Phase 4
Development phase
12
Enrollment target

NCT00767572 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00767572, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.

TERMINATED
Registry status
Phase 4
Development phase
12 participants
Enrollment target

Study Summary

Coarctation of the aorta (CoA) accounts for approximately 8% of all congenital heart problems. Patients with CoA are well known to have an increased rates of early heart disease, high blood pressure, heart failure and stroke. Abnormal arterial function (dilation and constriction of the blood vessels) has been observed in these patients and likely contributes to the increased risk of cardiovascular problems. However, therapies targeted at improving arterial function have not been investigated in this population. Statin therapy (cholesterol medicines like Lipitor) have been studied in other subgroups of patients with abnormal arterial function and has shown benefit in improving arterial function and reducing risk of cardiovascular problems. The investigators hypothesize that patients with CoA have abnormal arterial function leading to increased cardiovascular risk. We further hypothesize that statin therapy may improve this problem. We plan to compile a complete database of information regarding these patients cardiovascular health and propose to then examine the effect of atorvastatin (Lipitor) on arterial function as measured by changes in arm arterial function tests.

Interventions

  • DRUG atorvastatin
  • DRUG Sugar pill

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2008-08
Est. Completion 2010-07
Phase Phase 4

What the Registry Record Tells You About NCT00767572

The ClinicalTrials.gov registry entry for NCT00767572 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which atorvastatin is the first listed.

NCT00767572 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00767572 about?

NCT00767572 is a clinical study titled "Statins and Endothelial Function in Patients With Coarctation of the Aorta". Coarctation of the aorta (CoA) accounts for approximately 8% of all congenital heart problems. Patients with CoA are well known to have an increased rates of early heart disease, high blood pressure, heart failure and stroke. Abnormal arterial function (dilation and constriction of the blood vessels...

What is the current status of trial NCT00767572?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2008-08. Estimated completion is 2010-07.

What interventions are being tested in trial NCT00767572?

The interventions under investigation include: atorvastatin (DRUG), Sugar pill (DRUG).

Who is sponsoring clinical trial NCT00767572?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.